Top government and company officials joined local executives and employees as Fresenius Kabi inaugurated yesterday the major expansion of the company's production site in the
In Haina, just outside the
President
'We are proud to continue and further develop our decades-long presence in this region, and we are very excited about this expanded facility,' Henriksson said. 'This is yet another step in improving the lives of chronically and critically ill people around the world. We all look forward to putting ever more leading-edge disposables and devices in the hands of the people who are caring for patients and collecting life-saving plasma donations.'
Fresenius Kabi's first plant building at the Haina site, which opened in 1987, covers around 18,000 square meters (195,000 square feet). The expansion, in which Fresenius Kabi is investing more than
A global healthcare company specializing in life-saving medicines and technologies for infusion, transfusion and clinical nutrition, Fresenius Kabi has almost 40,000 employees worldwide, including more than 3,500 in Haina. The life-saving disposables for transfusion medicine and cell technologies manufactured in Haina are exported to global markets to make a difference in the quality of life of patients worldwide.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection and processing of blood and cell components.
Fresenius Kabi employs over 37,000 people worldwide. In 2018 the company reported sales of more than
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.
Management Board:
Dr.
Chairman of the Supervisory Board:
Registered Office: Bad Homburg,
Contact:
Tel: +49 6172 686 2627
(C) 2020 Electronic News Publishing, source